Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development

Medicine & Life Sciences

• Protein C Inhibitor 100%
• Cyclin-Dependent Kinases 98%
• Protein Kinase Inhibitors 88%
• Antineoplastic Agents 80%
• Protein Kinase C 79%
• Apoptosis 42%
• Phosphotransferases 32%
• Cell Cycle Checkpoints 27%
• Catalytic Domain 25%
• Drug Therapy 24%
• protein kinase C kinase 19%
• Protein-Serine-Threonine Kinases 15%
• Cell Cycle 11%
• Clinical Trials 9%
• Cell Line 8%
• Growth 7%
• Pharmaceutical Preparations 5%
• Neoplasms 4%
• Therapeutics 2%